Loading
Viridian Therapeutics, Inc.\DE Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 27 Oct 2025.
Viridian Therapeutics, Inc.\DE: what insiders have been doing
This page follows insider dealings at Viridian Therapeutics, Inc.\DE as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 7 insiders published 15 filings.
Both sides are active: 1 purchase worth €8.6M and 3 sales worth €361k, from 1 insider and 1 insider respectively. On balance, insiders were net buyers of €8.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €8.6M by Fairmount Funds Management LLC, published on 27 October 2025. Among those who bought: 1 senior executive.
The most recent open-market purchase was published on 27 October 2025, 356 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,458 companies, median 22 filings), a count of 15 filings is below the norm. Looking back to 2016, when coverage begins, insiders filed 10 purchases and 10 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
47
Thresholds
n/a
Buy Volume
€66M
10 ops. · all time
Sell Volume
€5M
10 ops. · all time
Who traded when
BuySaleJennifer Tousignant3 sales
Fairmount Funds Management LLC1 buy
Since the insiders bought
- +42.7%Entry US$23.17 · Close at T+90 US$33.06
- -9.9%Entry US$23.61 · Close at T+365 US$21.27
- -9.9%Entry US$23.61 · Close at T+365 US$21.27
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Viridian Therapeutics, Inc.\DE Strong Buy (bullish), based on 16 analysts. Average price target: US$36.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$18.38
Analyst consensus
16 analystsStrong buy
US$22.00Target US$36.75(+100%)US$50.00
Income statement
RevenueUS$70.8M
EBITDA-US$337.2M-476% margin
Net income-US$342.6M-483.6% margin
Valuation
PER (forward)-6.7x
P/Book3.7x
Beta1.10
Balance sheet & cash
Market capUS$2.1B
Total debtUS$50.7M
Free Cash Flow-US$276.9M
Debt / Equity37%
Profitability & ownership
ROE-65.7%
ROA-30.2%
% insiders0.2%
% institutions126.8%
Last declaration on 20 August 2026
Declarations47 total
4,212 shares@ US$24.500.0042% mcap10.7% of flowCommon StockSEC:0001193125-26-359636:0
10,000 shares@ US$14.410.0058% mcap15.0% of flowCommon StockSEC:0001193125-26-359636:1
10,000 shares@ US$24.500.0099% mcap25.5% of flowCommon StockSEC:0001193125-26-359636:2
14,212 shares@ US$24.500.014% mcap36.3% of flowCommonSEC144:0001959173-26-006222
40,000 shares@ US$13.210.021% mcap100.0% of flowCommon StockSEC:0001193125-26-355735:0
7,408 shares@ US$30.1930.0% of flowCommon StockSEC:0001193125-26-099007:0
1,675 shares@ US$30.190.0019% mcap5.2% of flowCommon StockSEC:0001193125-26-099008:0
2,031 shares@ US$30.19100.0% of flowCommon StockSEC:0001193125-26-099023:0
3,048 shares@ US$30.1942.9% of flowCommon StockSEC:0001193125-26-099014:0
9,409 sharesCommon StockSEC:0001193125-26-092040:0
5,169 sharesCommon StockSEC:0001193125-26-092074:0
6,267 sharesCommon StockSEC:0001193125-26-092071:0
18,357 sharesCommon StockSEC:0001193125-26-092036:0
2,272 shares@ US$31.167.3% of flowCommon StockSEC:0001193125-26-001097:0
454,545 shares@ US$22.0013.6% of flowCommon StockSEC:0001104659-25-102606:0
Canonical exit: 21 Jan 2026 (T+90)
1,600 shares@ US$7.800.0% of flowCommon StockSEC:0001104659-25-058580:0
5,000 shares@ US$23.4157.1% of flowCommon StockSEC:0000950170-24-110485:0
Canonical exit: 26 Dec 2024 (T+90)
21,400 shares@ US$23.3370.0% of flowCommon StockSEC:0000950170-24-110484:0
Canonical exit: 26 Dec 2024 (T+90)
1,600,000 shares@ US$18.7542.8% of flowCommon StockSEC:0001104659-24-100769:0
Canonical exit: 12 Dec 2024 (T+90)
5,859 sharesCommon StockSEC:0000950170-24-039599:0
476,190 shares@ US$21.0014.5% of flowCommon StockSEC:0000950170-24-007123:0
Canonical exit: 21 Apr 2024 (T+90)
2,269 shares@ US$23.034.2% of flowCommon StockSEC:0000899243-23-015998:0
1,875 shares@ US$14.002.1% of flowCommon StockSEC:0000899243-23-014615:0
4,000 shares@ US$25.369738.1% of flowCommon StockSEC:0000950170-23-012595:0
Canonical exit: 11 Jul 2023 (T+90)
5,500 shares@ US$29.149961.9% of flowCommon StockSEC:0000950170-23-007570:0
Canonical exit: 11 Jun 2023 (T+90)
25 of 47 declarations
About Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc. is a US biotechnology company listed on the Nasdaq market (United States) under the ticker VRDN. Headquartered in Waltham, Massachusetts, Viridian is focused on developing potentially best-in-class medicines for autoimmune and rare diseases, with its most advanced and commercially relevant efforts centered on thyroid eye disease (TED). The company was originally founded in January 2010 as a Delaware LLC, later incorporated in June 2014, and adopted the Viridian Therapeutics name following the merger with miRagen Therapeutics in January 2021. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm?utm_source=openai))
Viridian’s business model is built around antibody discovery and protein engineering. Rather than pursuing entirely novel biology for its own sake, the company targets clinically validated pathways where existing therapies leave meaningful unmet need, aiming to improve efficacy, tolerability, and convenience. That framework is especially visible in TED, an autoimmune disease that can cause eye bulging, pain, double vision, and loss of quality of life. Viridian has framed its mission as improving treatment options for patients with autoimmune and rare diseases and has repeatedly emphasized differentiated clinical activity and easier administration as core design goals. ([viridiantherapeutics.com](https://www.viridiantherapeutics.com/about/?utm_source=openai))
Read moreShow less
The company’s lead assets are veligrotug, formerly VRDN-001, an intravenous anti-IGF-1R antibody, and elegrobart, formerly VRDN-003, a subcutaneous anti-IGF-1R candidate designed for more convenient delivery. Both programs have generated positive Phase 3 data in active and chronic TED. In 2025, Viridian received FDA Breakthrough Therapy Designation for veligrotug, submitted its BLA, and obtained Priority Review with a PDUFA target action date of June 30, 2026. In 2026, the company also reported positive topline data from the REVEAL-1 and REVEAL-2 Phase 3 studies for elegrobart, strengthening the commercial and clinical case for a broader TED franchise. ([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Receives-FDA-Breakthrough-Therapy-Designation-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease-TED/default.aspx?utm_source=openai))
From a competitive standpoint, Viridian is trying to differentiate itself through a combination of clinical potency, fewer infusions, and, for the subcutaneous version, potentially improved patient convenience and physician adoption. Management has said the goal is to establish veligrotug and elegrobart as foundational therapies in TED, with U.S. launch preparation underway and a European filing strategy also in motion. Beyond TED, the pipeline includes earlier-stage programs such as VRDN-006 and VRDN-008, as well as other autoimmune-focused assets, suggesting that TED is the first commercial platform rather than the company’s only long-term opportunity. ([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Highlights-Recent-Progress-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results?utm_source=openai))
For investors, Viridian is best viewed as a catalyst-driven biotech with meaningful execution risk but substantial upside if regulatory and launch milestones are met. Recent headlines have centered on the veligrotug regulatory path, positive elegrobart readouts, and a strengthened balance sheet, all of which support the company’s transition from pure R&D toward potential commercialization. ([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Elegrobart-Phase-3-REVEAL1-Clinical-Trial-in-Active-Thyroid-Eye-Disease/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
